Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1972 1
1974 1
1975 4
1976 1
1977 3
1978 5
1979 15
1980 8
1981 10
1982 4
1983 8
1984 14
1985 15
1986 15
1987 18
1988 17
1989 23
1990 31
1991 22
1992 25
1993 38
1994 27
1995 43
1996 45
1997 56
1998 46
1999 61
2000 53
2001 55
2002 52
2003 55
2004 63
2005 71
2006 90
2007 87
2008 97
2009 91
2010 91
2011 126
2012 98
2013 111
2014 119
2015 110
2016 106
2017 114
2018 103
2019 112
2020 114
2021 103
2022 82
2023 87
2024 36

Text availability

Article attribute

Article type

Publication date

Search Results

2,485 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Breast Carcinoma Metastatic in the Bone"
Page 1
A vertebral skeletal stem cell lineage driving metastasis.
Sun J, Hu L, Bok S, Yallowitz AR, Cung M, McCormick J, Zheng LJ, Debnath S, Niu Y, Tan AY, Lalani S, Morse KW, Shinn D, Pajak A, Hammad M, Suhardi VJ, Li Z, Li N, Wang L, Zou W, Mittal V, Bostrom MPG, Xu R, Iyer S, Greenblatt MB. Sun J, et al. Nature. 2023 Sep;621(7979):602-609. doi: 10.1038/s41586-023-06519-1. Epub 2023 Sep 13. Nature. 2023. PMID: 37704733 Free PMC article.
Vertebral bone is subject to a distinct set of disease processes from long bones, including a much higher rate of solid tumour metastases(1-4). ...Multiple lines of evidence indicate that vSSCs contribute to the high rates of vertebral metastatic tropism o …
Vertebral bone is subject to a distinct set of disease processes from long bones, including a much higher rate of solid tumour …
Updated recommendations regarding the management of older patients with breast cancer: a joint paper from the European Society of Breast Cancer Specialists (EUSOMA) and the International Society of Geriatric Oncology (SIOG).
Biganzoli L, Battisti NML, Wildiers H, McCartney A, Colloca G, Kunkler IH, Cardoso MJ, Cheung KL, de Glas NA, Trimboli RM, Korc-Grodzicki B, Soto-Perez-de-Celis E, Ponti A, Tsang J, Marotti L, Benn K, Aapro MS, Brain EGC. Biganzoli L, et al. Lancet Oncol. 2021 Jul;22(7):e327-e340. doi: 10.1016/S1470-2045(20)30741-5. Epub 2021 May 14. Lancet Oncol. 2021. PMID: 34000244 Review.
These guidelines were expanded to include chemotherapy toxicity prediction calculators, cultural and social considerations, surveillance imaging, genetic screening, gene expression profiles, neoadjuvant systemic treatment options, bone-modifying drugs, targeted ther …
These guidelines were expanded to include chemotherapy toxicity prediction calculators, cultural and social considerations, surveilla …
Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases: A Randomized Clinical Trial.
Himelstein AL, Foster JC, Khatcheressian JL, Roberts JD, Seisler DK, Novotny PJ, Qin R, Go RS, Grubbs SS, O'Connor T, Velasco MR Jr, Weckstein D, O'Mara A, Loprinzi CL, Shapiro CL. Himelstein AL, et al. JAMA. 2017 Jan 3;317(1):48-58. doi: 10.1001/jama.2016.19425. JAMA. 2017. PMID: 28030702 Free PMC article. Clinical Trial.
DESIGN, SETTING, PARTICIPANTS: Randomized, open-label clinical trial conducted at 269 academic and community sites in the United States. Patients (n = 1822) with metastatic breast cancer, metastatic prostate cancer, or multiple myeloma who had at least 1 site …
DESIGN, SETTING, PARTICIPANTS: Randomized, open-label clinical trial conducted at 269 academic and community sites in the United States. Pat …
Randomized Trial Comparing Resection of Primary Tumor with No Surgery in Stage IV Breast Cancer at Presentation: Protocol MF07-01.
Soran A, Ozmen V, Ozbas S, Karanlik H, Muslumanoglu M, Igci A, Canturk Z, Utkan Z, Ozaslan C, Evrensel T, Uras C, Aksaz E, Soyder A, Ugurlu U, Col C, Cabioglu N, Bozkurt B, Uzunkoy A, Koksal N, Gulluoglu BM, Unal B, Atalay C, Yıldırım E, Erdem E, Salimoglu S, Sezer A, Koyuncu A, Gurleyik G, Alagol H, Ulufi N, Berberoglu U, Dulger M, Cengiz O, Sezgin E, Johnson R. Soran A, et al. Ann Surg Oncol. 2018 Oct;25(11):3141-3149. doi: 10.1245/s10434-018-6494-6. Epub 2018 May 17. Ann Surg Oncol. 2018. PMID: 29777404 Clinical Trial.
Unplanned subgroup analyses showed that the risk of death was statistically lower in the LRT group than in the ST group with respect to estrogen receptor (ER)/progesterone receptor (PR)(+) (HR 0.64; 95% CI 0.46-0.91; p = 0.01), human epidermal growth factor 2 (HER2)/neu(-) (HR 0. …
Unplanned subgroup analyses showed that the risk of death was statistically lower in the LRT group than in the ST group with respect to estr …
CAPG and GIPC1: Breast Cancer Biomarkers for Bone Metastasis Development and Treatment.
Westbrook JA, Cairns DA, Peng J, Speirs V, Hanby AM, Holen I, Wood SL, Ottewell PD, Marshall H, Banks RE, Selby PJ, Coleman RE, Brown JE. Westbrook JA, et al. J Natl Cancer Inst. 2016 Jan 12;108(4):djv360. doi: 10.1093/jnci/djv360. Print 2016 Apr. J Natl Cancer Inst. 2016. PMID: 26757732 Free PMC article.
BACKGROUND: Bone is the predominant site of metastasis from breast cancer, and recent trials have demonstrated that adjuvant bisphosphonate therapy can reduce bone metastasis development and improve survival. ...METHODS: Potential biomarkers for bone m …
BACKGROUND: Bone is the predominant site of metastasis from breast cancer, and recent trials have demonstrated that adjuvant b …
The endocrine influence on the bone microenvironment in early breast cancer.
Wilson C, Brown H, Holen I. Wilson C, et al. Endocr Relat Cancer. 2016 Dec;23(12):R567-R576. doi: 10.1530/ERC-16-0238. Epub 2016 Sep 29. Endocr Relat Cancer. 2016. PMID: 27687494 Free article. Review.
Multiple factors influence the survival of disseminated breast tumour cells (DTCs) in bone. Whereas gene signature studies have identified genes that predict a propensity of tumours to metastasise to bone, the bone environment is key in determin …
Multiple factors influence the survival of disseminated breast tumour cells (DTCs) in bone. Whereas gene signature studies hav …
Novel Techniques to Study the Bone-Tumor Microenvironment.
Shupp AB, Kolb AD, Bussard KM. Shupp AB, et al. Adv Exp Med Biol. 2020;1225:1-18. doi: 10.1007/978-3-030-35727-6_1. Adv Exp Med Biol. 2020. PMID: 32030644 Review.
In this chapter we review innovative techniques and model systems that can be used to study bidirectional crosstalk between cancer cells and stromal cells in the bone, with an emphasis specifically on bone-metastatic breast cancer. Investigating how …
In this chapter we review innovative techniques and model systems that can be used to study bidirectional crosstalk between cancer cells and …
Engineering the early bone metastatic niche through human vascularized immuno bone minitissues.
Colombo MV, Bersini S, Arrigoni C, Gilardi M, Sansoni V, Ragni E, Candiani G, Lombardi G, Moretti M. Colombo MV, et al. Biofabrication. 2021 Apr 26;13(3). doi: 10.1088/1758-5090/abefea. Biofabrication. 2021. PMID: 33735854
Bone metastases occur in 65%-80% advanced breast cancer patients. ...The minitissue reflects breast CC organ-specific metastatization to bone compared to a muscle minitissue. ...
Bone metastases occur in 65%-80% advanced breast cancer patients. ...The minitissue reflects breast CC organ-specific …
Metastasis prevention with bone-targeted agents: a complex interaction between the microenvironment and tumour biology.
Coleman R. Coleman R. J Bone Miner Metab. 2023 May;41(3):290-300. doi: 10.1007/s00774-023-01434-x. Epub 2023 May 10. J Bone Miner Metab. 2023. PMID: 37162605 Review.
INTRODUCTION: The use of bone-targeted treatments has transformed the clinical care of many patients with metastatic breast cancer. ...Results show that in breast cancer the use of adjuvant bisphosphonates reduce bone metastases and breast …
INTRODUCTION: The use of bone-targeted treatments has transformed the clinical care of many patients with metastatic breast …
Bisphosphonates and breast carcinoma: present and future.
Lipton A. Lipton A. Cancer. 2000 Jun 15;88(12 Suppl):3033-7. doi: 10.1002/1097-0142(20000615)88:12+<3033::aid-cncr20>3.3.co;2-3. Cancer. 2000. PMID: 10898348 Review.
Finally, tumor cells staining strongly for matrix metalloproteinases are observed in osteolytic pathologic bone fractures secondary to metastatic carcinoma. In many of these lesions frequent tumor cells are observed and osteoclasts are ra …
Finally, tumor cells staining strongly for matrix metalloproteinases are observed in osteolytic pathologic bone fractures s …
2,485 results